Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 735

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 735
---
Rx ®every three months to prolong the observed therapeutic effect. As detailed above, as part of the Phase I/IIa clinical trial carried out by the company in Israel between 2018 – 2020. At the same time as conducting the clinical trials, the company intends to continue developing closed and automated production processes that will answer the commercial production phase for thousands of patients once the clinical phases are successful. The company estimates that it will be ready to start the multi -siteclinical trial during the fourth quarter of 2025, subject to obtaining the required funding for the experiment. Like the support that AstroRx ®cells provide to the motor neurons survival in ALS disease, the astrocyte cells support the survival of nerve cells that are damaged in other neurodegenerative diseases. The company’s progress in the process of development, production, regulation, and clinical assessment of the AstroRx ®product in the use of these cells in the ALS disease may serve a rapid and efficient development of the product for additional indications,

| Moore Financial Consulting |

Annex E-9

thus shortening the arrival of the product to clinical stages in a relatively short period of time and raising the business potential of the company, the company intends to examine the possibilities for reviewing the effectiveness of the cellular product in supporting the survival of nerve cells in other neurodegenerative diseases such as the advanced stage of Multiple Sclerosis, Glaucoma, Parkinson and Alzheimer. IsletRx IsletRx’s cellular product is based on pluripotent stem cells expansion and differentiation. It received as part of non -exclusivelicense agreements and on its technological platform, which enables the proliferation of pluripotent stem cells and their differentiation into cells like the islets of Langerhans (which contain insulin -producingbeta cells and glucagon -producingalpha cells). These cells are intended for transplantation in diabetics whose beta cells are unable to produce insulin and release it in response to an increase in blood sugar. Transplantation of the cells will restore the patient’s ability to produce and release insulin biologically as needed, independently of external monitoring of the blood sugar level and regular insulin injections. Therefore, the company’s drug is intended for type 1 and type 2 diabetes patients who depend on insulin injection from an external source to maintain adequate blood glucose levels. The treatment is based on islet -likeclusters of cells produced from pluripotent stem cells. As described above, based on extensive clinical trials conducted worldwide (end of the third phase) with the help of